WZWelmoed Van Zuiden

Welmoed Van Zuiden

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Welmoed Van Zuiden has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    TDP-43 toxic gain of function links ALS, FTD and Alzheimer's disease via mis-splicing

    by Welmoed Van Zuiden, Thea D Meimoun, Chen Bar, Aviad Siany, Lihi Moshe, Nancy S Yacovzada, Eviatar Weizman, Manuela Neumann, Aron S Buchman, Yanling Wang, et al.

    TDP-43 proteinopathy is a hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). It is also common in Alzheimer's disease (AD) and limbic-predominant age-related TDP-43 encephalopathy (LATE), but its functional consequences are unclear. Here, we show that TDP-43 pathology in AD is broadly associated with splicing abnormalities. We define a conserved TDP-43-dependent splicing signature in AD that includes AD-relevant mis-spliced mRNAs such as amyloid precursor protein (APP). TDP-43 drives the formation of elongated APP isoforms across ALS, FTLD-TDP and AD, providing a mechanism for the long-standing observation of APP isoform dysregulation. APP isoform imbalance correlates with and partially mediates the association between TDP-43 pathology and Aβ burden and is spatially associated with pTDP-43 and mis-spliced STMN2 in LATE hippocampus. Contrary to a pure nuclear loss-of-function model, mis-splicing is driven by cytoplasmic TDP-43 gain-of-function that co-sequesters splicing-regulatory RNA-binding proteins. Knockdown of TDP-43-associated RNA-binding proteins recapitulates disease-relevant splicing changes in AD and ALS/FTLD-TDP, and some of these proteins colocalize with cytoplasmic pTDP-43 in neuropathological samples. Our findings establish cytoplasmic TDP-43-driven splicing dysfunction as a key component of neurodegeneration, define disease-relevant mis-spliced mRNAs in AD and unite AD with ALS/FTLD-TDP through a shared mechanism of splicing factor sequestration.


  • Open Access

    Organellomics: AI-driven deep organellar phenotyping reveals novel ALS mechanisms in human neurons

    by Sagy Krispin, Welmoed van Zuiden, Yehuda M. Danino, Noam Rudberg, Lena Molitor, Bar Abarbanel, Gal Aviram, Gili Wolf, Chen Bar, Aviad Siani, et al.

    Systematic assessment of organelle architectures, termed the organellome , offers valuable insights into cellular states and pathomechanisms, but remains largely uncharted. Here, we present a deep phenotypic learning based on vision transformers, resulting in the Neuronal Organellomics Vision Atlas (NOVA) model that studies confocal images of more than 30 markers of distinct membrane-bound and membraneless organelles in 11.5 million images of human neurons. Organellomics analysis quantifies perturbation-induced changes in organelle localization and morphology using a rigorous mixed-effects meta-analytic framework that accounts for sampling variance and experimental heterogeneity. Applying this approach, we delineate phenotypic alterations in neurons carrying ALS-associated mutations and uncover a physical and functional crosstalk between cytoplasmic mislocalized TDP-43, a hallmark of ALS, and processing bodies (P-bodies), membraneless organelles regulating mRNA stability. These findings are validated in patient-derived neurons and human neuropathology. NOVA establishes a scalable framework for quantitative mapping of subcellular phenotypes and provides a new avenue for investigating the neurocellular basis of disease.